Do analysts prefer APT or OBIO?

Orchestra BioMed has a consensus price target of $13.60, suggesting a potential upside of 255.09%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than Alpha Pro Tech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Pro Tech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Orchestra BioMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Do analysts rate RXST or APT?

RxSight presently has a consensus target price of $9.44, suggesting a potential upside of 98.83%. Given RxSight's stronger consensus rating and higher possible upside, equities research analysts clearly believe RxSight is more favorable than Alpha Pro Tech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 3 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.93 Alpha Pro Tech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is RXST or APT more profitable?

Alpha Pro Tech has a net margin of 6.99% compared to RxSight's net margin of -36.58%. Alpha Pro Tech's return on equity of 6.70% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% Alpha Pro Tech 6.99% 6.70% 5.76%

Do analysts recommend APT or PDEX?

Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 4.01%. Given Pro-Dex's stronger consensus rating and higher possible upside, analysts plainly believe Pro-Dex is more favorable than Alpha Pro Tech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Pro Tech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pro-Dex 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings and valuation, APT or PDEX?

Pro-Dex has higher revenue and earnings than Alpha Pro Tech. Alpha Pro Tech is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Pro Tech $59.91M 0.90 $4.19M $0.35 15.11 Pro-Dex $66.59M 3.22 $8.98M $3.62 18.59

Is APT or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Alpha Pro Tech's net margin of 6.99%. Pro-Dex's return on equity of 22.78% beat Alpha Pro Tech's return on equity. Company Net Margins Return on Equity Return on Assets Alpha Pro Tech 6.99% 6.70% 5.76% Pro-Dex 16.08% 22.78% 14.30%

Do analysts recommend SMTI or APT?

Sanara MedTech currently has a consensus price target of $34.00, indicating a potential upside of 59.40%. Given Sanara MedTech's stronger consensus rating and higher possible upside, research analysts plainly believe Sanara MedTech is more favorable than Alpha Pro Tech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanara MedTech 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Alpha Pro Tech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Alpha Pro Tech (APT) Competitors

$5.29 -0.17 (-3.11%)

As of 12:20 PM Eastern

Compare

APT vs. OBIO, RXST, TMCI, PDEX, and SMTI

Should you buy Alpha Pro Tech stock or one of its competitors? MarketBeat compares Alpha Pro Tech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Pro Tech include Orchestra BioMed (OBIO), RxSight (RXST), Treace Medical Concepts (TMCI), Pro-Dex (PDEX), and Sanara MedTech (SMTI). These companies are all part of the "medical equipment" industry.

How does Alpha Pro Tech compare to Orchestra BioMed?

Alpha Pro Tech (NYSE:APT) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

22.7% of Alpha Pro Tech shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 15.0% of Alpha Pro Tech shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Alpha Pro Tech has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Pro Tech	$59.91M	0.90	$4.19M	$0.35	15.11
Orchestra BioMed	$33.48M	6.85	-$52.70M	-$0.97	N/A

In the previous week, Orchestra BioMed had 6 more articles in the media than Alpha Pro Tech. MarketBeat recorded 6 mentions for Orchestra BioMed and 0 mentions for Alpha Pro Tech. Orchestra BioMed's average media sentiment score of 1.89 beat Alpha Pro Tech's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Overall Sentiment
Alpha Pro Tech	Neutral
Orchestra BioMed	Very Positive

Alpha Pro Tech has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Alpha Pro Tech has a net margin of 6.99% compared to Orchestra BioMed's net margin of -166.96%. Alpha Pro Tech's return on equity of 6.70% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Pro Tech	6.99%	6.70%	5.76%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

Orchestra BioMed has a consensus price target of $13.60, suggesting a potential upside of 255.09%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Alpha Pro Tech beats Orchestra BioMed on 9 of the 16 factors compared between the two stocks.

How does Alpha Pro Tech compare to RxSight?

RxSight (NASDAQ:RXST) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

78.8% of RxSight shares are held by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 15.0% of Alpha Pro Tech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

RxSight has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Alpha Pro Tech has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

In the previous week, RxSight had 2 more articles in the media than Alpha Pro Tech. MarketBeat recorded 2 mentions for RxSight and 0 mentions for Alpha Pro Tech. RxSight's average media sentiment score of 0.93 beat Alpha Pro Tech's score of 0.00 indicating that RxSight is being referred to more favorably in the media.

Company	Overall Sentiment
RxSight	Positive
Alpha Pro Tech	Neutral

RxSight presently has a consensus target price of $9.44, suggesting a potential upside of 98.83%. Given RxSight's stronger consensus rating and higher possible upside, equities research analysts clearly believe RxSight is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Alpha Pro Tech has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.54	-$38.94M	-$1.13	N/A
Alpha Pro Tech	$59.91M	0.90	$4.19M	$0.35	15.11

Alpha Pro Tech has a net margin of 6.99% compared to RxSight's net margin of -36.58%. Alpha Pro Tech's return on equity of 6.70% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Alpha Pro Tech	6.99%	6.70%	5.76%

Summary

RxSight beats Alpha Pro Tech on 9 of the 16 factors compared between the two stocks.

How does Alpha Pro Tech compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Treace Medical Concepts had 9 more articles in the media than Alpha Pro Tech. MarketBeat recorded 9 mentions for Treace Medical Concepts and 0 mentions for Alpha Pro Tech. Treace Medical Concepts' average media sentiment score of 1.52 beat Alpha Pro Tech's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company	Overall Sentiment
Treace Medical Concepts	Very Positive
Alpha Pro Tech	Neutral

Alpha Pro Tech has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	1.04	-$59M	-$0.97	N/A
Alpha Pro Tech	$59.91M	0.90	$4.19M	$0.35	15.11

Treace Medical Concepts has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Alpha Pro Tech has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Alpha Pro Tech has a net margin of 6.99% compared to Treace Medical Concepts' net margin of -29.44%. Alpha Pro Tech's return on equity of 6.70% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-29.44%	-67.04%	-30.28%
Alpha Pro Tech	6.99%	6.70%	5.76%

Treace Medical Concepts currently has a consensus price target of $4.77, indicating a potential upside of 39.47%. Given Treace Medical Concepts' stronger consensus rating and higher probable upside, equities research analysts clearly believe Treace Medical Concepts is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 15.0% of Alpha Pro Tech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Treace Medical Concepts beats Alpha Pro Tech on 10 of the 16 factors compared between the two stocks.

How does Alpha Pro Tech compare to Pro-Dex?

Alpha Pro Tech (NYSE:APT) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Pro-Dex has higher revenue and earnings than Alpha Pro Tech. Alpha Pro Tech is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Pro Tech	$59.91M	0.90	$4.19M	$0.35	15.11
Pro-Dex	$66.59M	3.22	$8.98M	$3.62	18.59

In the previous week, Pro-Dex had 2 more articles in the media than Alpha Pro Tech. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for Alpha Pro Tech. Pro-Dex's average media sentiment score of 0.18 beat Alpha Pro Tech's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
Alpha Pro Tech	Neutral
Pro-Dex	Neutral

22.7% of Alpha Pro Tech shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 15.0% of Alpha Pro Tech shares are held by company insiders. Comparatively, 45.9% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 4.01%. Given Pro-Dex's stronger consensus rating and higher possible upside, analysts plainly believe Pro-Dex is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alpha Pro Tech has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

Pro-Dex has a net margin of 16.08% compared to Alpha Pro Tech's net margin of 6.99%. Pro-Dex's return on equity of 22.78% beat Alpha Pro Tech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Pro Tech	6.99%	6.70%	5.76%
Pro-Dex	16.08%	22.78%	14.30%

Summary

Pro-Dex beats Alpha Pro Tech on 14 of the 16 factors compared between the two stocks.

How does Alpha Pro Tech compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Alpha Pro Tech has lower revenue, but higher earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	1.89	-$37.56M	-$3.77	N/A
Alpha Pro Tech	$59.91M	0.90	$4.19M	$0.35	15.11

Alpha Pro Tech has a net margin of 6.99% compared to Sanara MedTech's net margin of -31.23%. Alpha Pro Tech's return on equity of 6.70% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Alpha Pro Tech	6.99%	6.70%	5.76%

Sanara MedTech has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Alpha Pro Tech has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 15.0% of Alpha Pro Tech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sanara MedTech currently has a consensus price target of $34.00, indicating a potential upside of 59.40%. Given Sanara MedTech's stronger consensus rating and higher possible upside, research analysts plainly believe Sanara MedTech is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Sanara MedTech had 3 more articles in the media than Alpha Pro Tech. MarketBeat recorded 3 mentions for Sanara MedTech and 0 mentions for Alpha Pro Tech. Sanara MedTech's average media sentiment score of 0.63 beat Alpha Pro Tech's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Overall Sentiment
Sanara MedTech	Positive
Alpha Pro Tech	Neutral

Summary

Sanara MedTech beats Alpha Pro Tech on 9 of the 16 factors compared between the two stocks.

Get Alpha Pro Tech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APT vs. The Competition

Export

Metric	Alpha Pro Tech	Surgical appliances & supplies Industry	Industrials Sector	NYSE Exchange
Market Cap	$54.05M	$23.62M	$9.62B	$23.13B
Dividend Yield	N/A	N/A	3.54%	4.09%
P/E Ratio	14.30	14.32	25.18	31.16
Price / Sales	0.90	1.55	5,101.41	14.72
Price / Cash	12.80	12.80	28.20	24.78
Price / Book	1.00	1.47	5.08	4.68
Net Income	$4.19M	-$3.92M	$794.09M	$1.07B
7 Day Performance	-9.11%	11.97%	0.65%	-0.38%
1 Month Performance	15.00%	16.53%	2.55%	0.52%
1 Year Performance	8.85%	-30.38%	30.75%	25.86%

Alpha Pro Tech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APT Alpha Pro Tech	N/A	$5.29 -3.1%	N/A	+10.8%	$54.05M	$59.91M	14.30	120
OBIO Orchestra BioMed	4.7857 of 5 stars	$3.96 -0.5%	$13.60 +243.4%	+23.7%	$236.53M	$33.48M	N/A	4	News Coverage Positive News
RXST RxSight	3.3041 of 5 stars	$5.55 -0.8%	$9.44 +70.2%	-68.2%	$229.56M	$134.48M	N/A	220
TMCI Treace Medical Concepts	3.4244 of 5 stars	$3.42 +10.9%	$4.77 +39.7%	-39.5%	$221.53M	$212.69M	N/A	250	Positive News Insider Trade Gap Up
PDEX Pro-Dex	2.0483 of 5 stars	$67.76 +0.4%	$70.00 +3.3%	+70.1%	$216.35M	$74.64M	18.72	140	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:APT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Pro Tech (APT) Competitors

APT vs. OBIO, RXST, TMCI, PDEX, and SMTI

How does Alpha Pro Tech compare to Orchestra BioMed?

Summary

How does Alpha Pro Tech compare to RxSight?

Summary

How does Alpha Pro Tech compare to Treace Medical Concepts?

Summary

How does Alpha Pro Tech compare to Pro-Dex?

Summary

How does Alpha Pro Tech compare to Sanara MedTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APT vs. The Competition

Alpha Pro Tech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Pro Tech (APT) Competitors

APT vs. OBIO, RXST, TMCI, PDEX, and SMTI

How does Alpha Pro Tech compare to Orchestra BioMed?

Do insiders & institutionals hold more shares of APT or OBIO?

Which has preferable valuation & earnings, APT or OBIO?

Does the media prefer APT or OBIO?

Which has more risk & volatility, APT or OBIO?

Is APT or OBIO more profitable?

Do analysts prefer APT or OBIO?

Summary

How does Alpha Pro Tech compare to RxSight?

Do insiders and institutionals hold more shares of RXST or APT?

Which has more risk & volatility, RXST or APT?

Does the media prefer RXST or APT?

Do analysts rate RXST or APT?

Which has preferable earnings & valuation, RXST or APT?

Is RXST or APT more profitable?

Summary

How does Alpha Pro Tech compare to Treace Medical Concepts?

Does the media refer more to TMCI or APT?

Which has stronger valuation and earnings, TMCI or APT?

Which has more volatility and risk, TMCI or APT?

Is TMCI or APT more profitable?

Do analysts prefer TMCI or APT?

Do insiders & institutionals hold more shares of TMCI or APT?

Summary

How does Alpha Pro Tech compare to Pro-Dex?

Which has better earnings and valuation, APT or PDEX?

Does the media prefer APT or PDEX?

Do institutionals and insiders hold more shares of APT or PDEX?

Do analysts recommend APT or PDEX?

Which has more volatility and risk, APT or PDEX?

Is APT or PDEX more profitable?

Summary

How does Alpha Pro Tech compare to Sanara MedTech?

Which has better earnings and valuation, SMTI or APT?

Is SMTI or APT more profitable?

Which has more risk & volatility, SMTI or APT?

Do institutionals & insiders have more ownership in SMTI or APT?

Do analysts recommend SMTI or APT?

Does the media refer more to SMTI or APT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APT vs. The Competition

Alpha Pro Tech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools